Table 3.
The risk factors in predicting patients with mild to moderate SARS-CoV-2 pneumonia conversion rate to severe cases
| Variable | Regression coefficient | Standard error | P value | Odds ratio | Lower OR | Upper OR |
|---|---|---|---|---|---|---|
| Age, years | -0·04 | 0·04 | 0·2376 | 0·96 | 0·90 | 1·03 |
| Gender (female vs. male) | −1·38 | 0·76 | 0·0702 | 0·25 | 0·06 | 1·12 |
| Fever (yes vs. no) | 1·13 | 0·60 | 0·0597 | 3·09 | 0·96 | 9·99 |
| Comorbidities (yes vs. no) | 0·87 | 0·86 | 0·3121 | 2·38 | 0·44 | 12·76 |
| C-reactive protein (< 10 mg/L vs.≧10 mg/L) | 0·38 | 0·75 | 0·6145 | 1·46 | 0·33 | 6·40 |
| Lymphocyte count (per reduced 0·1 × 109/L) | −0·25 | 0·09 | 0·0070 | 0·78 | 0·65 | 0·94 |
| Time from onset of illness to antiviral treatment, days | 0·03 | 0·06 | 0·6670 | 1·03 | 0·91 | 1·17 |
| Corticosteroids (yes vs. no) | −1·99 | 0·90 | 0·0275 | 0·14 | 0·02 | 0·80 |